Don’t just take our word for it! Let’s look at the data.

Wegovy is commonly associated with semaglutide therapies used for chronic weight management. Although Wegovy is typically an injectable brand, patients may search for oral or alternative presentations; we provide clear, evidence-based information regardless of form. Our pharmacists review eligibility, contraindications, and potential drug interactions, and can explain expected benefits and side effects. If a patient is prescribed a formulation, we ensure correct dosing, administration instructions, and safe storage. We also advise on lifestyle measures that complement medical treatment for better outcomes and long-term health.

The 64-week study included 307 adults with obesity (BMI ≥30 kg/m2) or adults with overweight (BMI ≥27 kg/m2) with at least one weight-related medical problem, including high blood pressure or high cholesterol. Adults with type 2 diabetes were excluded. Adults were randomly placed into 2 groups: 205 adults took Wegovy® pill once daily and 102 adults took a placebo (inactive) pill once daily.

All participants were told to eat a reduced-calorie diet and increase their physical activity, starting with their first dose and continuing through the study. During the trial, 18% of adults in the Wegovy® group discontinued treatment compared with 26% of adults in the placebo group.

When someone requests information about a Wegovy pill, we take a thorough medical history and check current medications to avoid interactions. Our pharmacists explain likely timelines for benefits, common adverse effects, and warning signs that require urgent attention. We can provide written information, demonstrate how to use or administer a product if relevant, and schedule follow-up contacts to review progress. For patients travelling or collecting on behalf of others, we advise on legal and safe handling. Our aim is to support safe, informed treatment decisions every step of the way.